Q2 EPS Estimates for Urogen Pharma Reduced by HC Wainwright

Urogen Pharma (NASDAQ:URGN - Free Report) - Stock analysts at HC Wainwright dropped their Q2 2025 EPS estimates for Urogen Pharma in a research note issued on Monday, June 16th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.80) per share for the quarter, down from their prior estimate of ($0.74). HC Wainwright currently has a "Buy" rating and a $50.00 price objective on the stock. The consensus estimate for Urogen Pharma's current full-year earnings is ($3.12) per share. HC Wainwright also issued estimates for Urogen Pharma's Q3 2025 earnings at ($0.69) EPS, Q4 2025 earnings at ($0.69) EPS, FY2025 earnings at ($3.10) EPS, Q1 2026 earnings at ($0.56) EPS, Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at $0.02 EPS, Q4 2026 earnings at $0.26 EPS and FY2026 earnings at $0.43 EPS.

Other research analysts have also issued research reports about the stock. The Goldman Sachs Group set a $16.00 price target on shares of Urogen Pharma and gave the stock a "neutral" rating in a report on Friday, June 13th. Oppenheimer set a $31.00 target price on shares of Urogen Pharma and gave the company a "buy" rating in a report on Friday, June 13th. Scotiabank reaffirmed an "outperform" rating on shares of Urogen Pharma in a research report on Friday, June 13th. D. Boral Capital reissued a "buy" rating and issued a $25.00 price objective on shares of Urogen Pharma in a research report on Thursday, June 12th. Finally, LADENBURG THALM/SH SH initiated coverage on Urogen Pharma in a research report on Wednesday, February 19th. They set a "buy" rating and a $31.00 target price on the stock. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Urogen Pharma presently has an average rating of "Buy" and a consensus target price of $32.86.

Urogen Pharma Trading Up 12.3%

Shares of Urogen Pharma stock traded up $1.63 during midday trading on Wednesday, reaching $14.87. The company had a trading volume of 3,965,606 shares, compared to its average volume of 1,030,493. The stock has a fifty day moving average price of $8.79 and a 200 day moving average price of $10.10. Urogen Pharma has a fifty-two week low of $3.42 and a fifty-two week high of $18.15. The firm has a market cap of $685.66 million, a PE ratio of -4.68 and a beta of 0.40. The company has a debt-to-equity ratio of 4.77, a current ratio of 5.65 and a quick ratio of 5.47.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The company had revenue of $20.25 million for the quarter, compared to analyst estimates of $22.71 million. Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 150.68%.

Insiders Place Their Bets

In other Urogen Pharma news, insider Mark Schoenberg sold 5,162 shares of the stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $7.37, for a total value of $38,043.94. Following the transaction, the insider now owns 153,378 shares in the company, valued at approximately $1,130,395.86. This represents a 3.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 5.10% of the company's stock.

Institutional Investors Weigh In On Urogen Pharma

Several hedge funds and other institutional investors have recently modified their holdings of the company. CWM LLC grew its holdings in shares of Urogen Pharma by 6,047.1% during the first quarter. CWM LLC now owns 5,225 shares of the company's stock valued at $58,000 after buying an additional 5,140 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in Urogen Pharma during the 4th quarter worth approximately $59,000. Lazard Asset Management LLC purchased a new stake in shares of Urogen Pharma in the fourth quarter worth approximately $67,000. GAMMA Investing LLC boosted its position in shares of Urogen Pharma by 6,908.4% during the first quarter. GAMMA Investing LLC now owns 7,499 shares of the company's stock valued at $83,000 after buying an additional 7,392 shares during the last quarter. Finally, Aquatic Capital Management LLC bought a new stake in Urogen Pharma during the fourth quarter worth $101,000. Institutional investors own 91.29% of the company's stock.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.